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Summary. Historically, multiplicity of actions in synthetic compounds is a rule rather than exception. The science of 
non-antibiotics evolved in this background. From the antimalarial and antitrypanosomial dye methylene blue, chemically 
similar compounds, the phenothiazines, were developed. The phenothiazines were first recognised for their antipsychotic 
properties, but soon after their antimicrobial functions came to be known and then such compounds were designated as 
non-antibiotics. The emergence of highly drug-resistant bacteria had initiated an urgent need to search for novel affordable 
compounds. Several phenothiazines awakened the interest among scientists to determine their antimycobacterial activity. 
Chlorpromazine, trifluoperazine, methdilazine and thioridazine were found to have distinct antitubercular action. Thioridazine 
took the lead as researchers repeatedly claimed its potentiality. Although thioridazine is known for its central nervous system 
and cardiotoxic side-effects, extensive and repeated in vitro and in vivo studies by several research groups revealed that a very 
small dose of thioridazine is required to kill tubercle bacilli inside macrophages in the lungs, where the bacteria try to remain 
and multiply silently. Such a small dose is devoid of its adverse side-effects. Recent studies have shown that the (–) thioridazine 
is a more active antimicrobial agent and devoid of the toxic side effects normally encountered. This review describes the possi-
bilities of bringing down thioridazine and its (–) form to be combined with other antitubercular drugs to treat infections by 
drug-resistant strains of Mycobacterium tuberculosis and try to eradicate this deadly disease. [Int Microbiol 2015; 18(1):1-12]
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Introduction
The origin of phenothiazine dates back to 1883, when German 
chemist August Heinrich Bernthsen was carrying out analyses 
to determine the chemical constituents of two dyes, Lauth’s 
violet and methylene blue. The dye methylene blue, whose 
chemical nucleus is phenothiazine, had been produced even 
earlier by another German, Heinrich Caro [11]. The dye in-
dustry originated in 1856 with William Perkin’s preparation 
of the first synthetic dye aniline purple. The increasing de-
mand of organic chemicals such as dyes promoted the 
develop ment of synthetic organic chemistry. It was soon re-
alised that knowing structure-activity relations of organic 
compounds was essential for the synthesis and manufacture 
of new dyes. Bernthsen synthesised the phenothiazine named 
as methylene blue on this background [11].
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One of the first major applications of phenothiazines be-
yond their use in dye industry was made in 1934 by ento-
mologists in the US Department of Agriculture. They pre-
pared dozens of synthetic organic sulphur compounds, among 
which, the most toxic compound for mosquito larvae was a 
phenothiazine, thiodiphenylamine [12]. Another important 
veterinary use of a synthetic phenothiazine was its application 
as an anthelmintic due to its effectiveness against swine asca-
ris [31]. The third action of phenothiazine to be known was its 
antimalarial activity reported in the extensive studies by Paul 
Guttmann and Paul Ehrlich [29] on methylene blue, which 
basically is a phenothiazine. In this connection, note that, al-
though Ehrlich was not involved directly with the diagnosis or 
therapy of tuberculosis, he was instrumental in the successful 
staining of tubercle bacilli. 
Robert Koch started his investigation staining and identi-
fying the infective organism of tuberculosis from the grey tu-
bercles in the lungs of animals that had died from tuberculo-
sis. On March 24, 1882, Koch reported, in a lecture in Berlin, 
his success in staining and cultivating tubercle bacilli from 
infected lung tissues [34]. Ehrlich, who was overwhelmed 
with the discovery, obtained a pure culture from Koch and 
experimented with his various stains. He used a shorter stain-
ing time and applied nitric acid and alcohol to decolourise the 
surrounding tissues. By accident, he learned the benefit of 
heating the slide where the staining was carried out. In May 
1882, Ehrlich published a detailed description of his staining 
technique [23]. Ehrlich’s improvement of the staining tech-
nique was soon acknowledged by Koch [50]. However, the 
first demonstration of a bacterium from a human infection had 
been made in 1875. Later Ziehl and Nielsen improved Eh-
rlich’s method and stained with carbol fuchsin so that the ba-
cilli became red and very prominently visible [59]. The work 
by Guttman and Ehrlich was confirmed much later by Four-
neau et al. [25], who synthesised many compounds by modi-
fying the main molecular structure of the phenothiazine meth-
ylene blue.
Syntheses and characterization of phe-
nothiazines
Halpern and Ducrot [30] synthesized many phenothiazine-
amine derivatives among which fenethazine was found to 
have a long lasting antihistaminic property. Charpentier et al. 
[14] described the synthesis of promethazine, which sur-
passed the action of fenethazine in its antihistaminic action; 
this was later used to treat motion sickness. 
Subsequently, many more phenothiazines were synthe-
sised to determine other effects. Bovet et al. [11] declared that 
their new phenothiazine compound diethazine had effects on 
sympathetic and parasympathetic nerve functions in dogs and 
rabbits. Macht and Hoffmaster [39] were the first to report on 
the use of conditioned reflex tests in animals to identify an 
effect of synthetic antihistamines on the central nervous sys-
tem. Winter and Flataker [58] described the central antihista-
minic effect of phenothiazines in animals with the help of the 
method of Macht and Mora [40]. They believed that the anti-
histaminic action of phenothiazines achieved their depressant 
effect by central action. The effect of phenothiazines could be 
nullified by caffeine to a large extent. Hence, they thought that 
cerebral cortex was the probable site of phenothiazine’s cen-
tral action. Their observations awoke the interest to synthesise 
many more phenothiazine compounds. 
In 1949, Henri Laborit, a French navy neurosurgeon, re-
ported on the use of antihistamines to combat circulatory 
shock during and after surgery. Laborit started using the phe-
nothiazine compound promethazine as potentiator for general 
anaesthesia and also to facilitate artificial hibernation in sur-
gery. Based on Laborit’s work, the French chemical company 
Rhône-Poulenc decided to synthesize many more such chem-
icals, which led to the synthesis of more than 4000 different 
phenothiazines. In 1951, Laborit received samples including 
chlorpromazine labelled as 4560RP from Rhône-Poulenc for 
his clinical and pharmacological studies to evaluate them as 
potentiators of anaesthesia in his surgical practice. Although 
he found these compounds useful for artificial hibernation, 
Laborit emphasised on the undeniable complexity of chlor-
promazine. Historically, the major impetus to move chlor-
promazine into psychiatry did not come directly from Rhône-
Poulenc. In fact, the studies carried out by Laborit and his 
co-workers were more responsible for the first trials of chlor-
promazine by French psychiatrists, including Sigwald and 
Bouthier [51], and Delay and Deniker [18], each team work-
ing independently in 1952. Thus, within a year chlorproma-
zine became world’s best choice for psychiatry.
Although the credit of having been the first miracle drug 
for psychiatry is given to chlorpromazine, in 1899 the Italian 
physician Pietro Bodoni [9] had demonstrated that methylene 
blue had sedative effect in a variety of psychotic conditions in 
his patients. Bodoni further suggested that methylene blue 
could be given to psychiatric patients on a regular basis [9]. 
However, when chlorpromazine came on the market, only a 
very few papers referred to the fact that chlorpromazine was a 
successor of methylene blue and also that all synthesised phe-
nothiazines and related compounds were antimicrobial and 
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neuroleptic, the so-called “narcobiotics.” Rhône-Poulenc was 
busy synthesizing various phenothiazines and distributing 
them to be tested in order to determine which of their com-
pounds should be the best neuroleptic for patients. Several 
researchers found that one particular compound labelled as 
3277 RP had antitubercular properties in vitro [37]. Such an 
antitubercular activity of chlorpromazine was obvious among 
different clinicians engaged in the treatment of psychoses and 
severe neuroses [27]. However, this unique function of chlor-
promazine was not considered for further development to call 
it and label it as an antimycobacterial drug due to the serious 
side-effects produced by its prolonged administration. Mean-
while isoniazid had come on the market in 1952 and its suc-
cess for treating patients suffering from Mycobacterium tu­
berculosis, coupled with information about other effective 
drugs, including streptomycin and rifampicin, lessened the 
chances of chlorpromazine being considered as an antimyco-
bacterial agent [16]. Nevertheless, studies from different parts 
of the world reported on the antimycobacterial properties of 
several phenothiazines, including chlorpromazine.
Reports of antimycobacterial pro perties 
in phenothiazines
Phenothiazines as a class of easily available compounds have 
been repeatedly reported to have a moderate to powerful ef-
fect against many clinical strains of Gram-positive and Gram-
negative bacteria both in vitro and in vivo [17]. Soon after the 
results of astounding success in treating neuroleptic patients 
with chlorpromazine became known, reports on its action 
against tuberculosis started appearing in scientific journals. 
One such important work was by Popper and Lorian [46] in 
1959, where the in vitro minimum inhibitory concentration 
(MIC) of chlorpromazine against M. tuberculosis was found 
to be as low as 25 mg/ml (Table 1). Subsequently, in 1961 
Bourdon [10] again proved that chlorpromazine had anti-tuber-
cular action in vitro. Those studies, however, did not create in-
terests in the development of chlorpromazine as a possible anti-
tubercular agent because of the terrible side-effects observed in 
patients receiving chlorpromazine in routine therapy. 
While studying the action of a few phenothiazines on dif-
ferent types of bacteria, Molnar et al. [42] described that the 
growth of M. tuberculosis, M. bovis and M. butyricum was 
inhibited by chlorpromazine practically at an identical con-
centration. The MICs for M. tuberculosis were 10 mg/ml for 
chlorpromazine and levomepromazine, 20 mg/ml for dietha-
zine and promethazine, whilst chlorpromazine sulfoxyde was 
ineffective even at 100 mg/ml. Both chlorpromazine and pro-
methazine exerted a measurable bactericidal activity on M. 
tuberculosis at 50 mg/ml; total destruction of the organism and 
partial loss of acid fastness of the cells could be observed at 
300 mg/ml of chlorpromazine. In 1986, Kristiansen and Verg-
mann [35] made an intensive research on the antibacterial ef-
fect of various phenothiazine and thioxanthene derivatives on 
different species of mycobacteria in vitro (Table 1). They ob-
served that the MICs of levomepromazine-maleate and chlor-
promazine against mycobacterial strains were 25 mg/ml and 
12.5 mg/ml, respectively. However, all stereo-isomers of clo-
penthixol were demonstrated to be twice as potent as chlor-
promazine, but equally potent as chlorprothixen. Again, fol-
lowing the same procedure, the stereo-isomeric compounds of 
flupenthixol were shown to be more efficient than those of 
clopenthixol and chlorprothixene.
All these observations suggested that the stereo-isomeric 
analogue of thioxanthene derivatives should have significant 
antibacterial activity against the slow-growing mycobacteria. 
This in vitro study also revealed that these compounds were 
effective with other resistant mycobacterial strains, including 
M. avium and M. intracellulare, within the same concentra-
tion range as mentioned earlier. Subsequently, chlorproma-
zine was tested by Crowle et al. [16] for its ability to inhibit 
the replication of M. tuberculosis and M. avium in cultured 
normal human macrophages, as determined by counts of via-
ble bacteria 0, 4, and 7 days after bacterial infection of the 
macrophages. Chlorpromazine was able to inhibit the intra-
cellular bacteria at concentrations ranging from 0.23 mg/ml to 
3.6 mg/ml, and was more effective intracellularly than extra-
cellularly (Table 1).
According to Ratnakar and Murthy [47], trifluoperazine, a 
known calmodulin antagonist, completely inhibits the growth 
of mycobacteria. In a synthetic medium containing 0.2% 
Tween 80, the MIC of this drug ranged from 5 to 8 mg/ml for 
the human pathogenic strain M. tuberculosis H37RV, and M. 
tuberculosis was resistant to isoniazid. When added to a grow-
ing culture of M. tuberculosis H37RV on the 10th day (mid ex-
ponential phase), trifluoperazine at the level of 50 mg/ml fur-
ther arrested growth of this organism. Those authors [47] also 
observed that trifluoperazine, at a concentration of 50 µg/ml, 
when added to the cells along with the labeled precursors, in-
hibited the incorporation of 14C acetate into lipids (63%) and 
uptake of 14C glycine (74%) and 3H thymidine (52%) by 
whole cells of M. tuberculosis H37RV, after 6 h of exposure. 
However, after 48 h, the inhibition was 87%, 97% and 74% 
respectively, in comparison with the labelled compounds as 
mentioned above. They further reported that when the drug 
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was added to cells taking up and metabolizing the labelled 
precursors at a later point 3 h for 14C acetate and 3H thymidine 
and 12 h for 14C glycine, trifluoperazine inhibited the uptake 
of all the precursors up to 24 h. It was suggested that this phe-
nothiazine would have multiple sites of action and acted prob-
ably by affecting the synthesis of lipids, proteins and DNA. 
Dastidar, Chakrabarty and their collaborators had worked 
on the detection and determination of antimicrobial action of 
Table 1. Distribution pattern of minimum inhibitory concentration (MIC) of different phenothiazines on 
clinical isolates of Mycobacterium tuberculosis
Phenothiazine MIC (µg/ml)  Method used Reference
Chlorpromazine 25 ADTa [46]
Chlorpromazine 12 ADT [10]
Chlorpromazine 10 ADT [42]
Levomepromazine 10
Promethazine 20
Diethazine 20
Chlorpromazine sulfoxide  >100
Chlorpromazine 12.5  ADT [35]
Levomepromazine 25
Trans (E)-flupenthixol  6.25
Cis (Z)-flupenthixol 6.25
Trans (E)-clopenthixol 12.5
Cis (Z)-clopenthixol 6.25
Trans (E)-chlorprothixen 6.25
Cis (Z)-chlorprothixen 12.5
Chlorpromazine 0.9 Macb [16]
Trifluoperazine 5–8 ADT [47]
Methildiazine 5–12.5 ADT [13]
Thioridazine 8-32 Bactecc [4]
Chlorpromazine 4–32 Bactecc [4]
Trifluoperazine 8–32 ADT [26]
Chlorpromazine*  10 Bactecc [44]
Chlorpromazine** 20–30
Thioridazine* 15
Thioridazine** 20–30
Thioridazine 4 ADT [54]
Trifluoperazine 2.5–7.5 ADT [3]
SILA 421 2–16 ADT [52]
Thioridazine  2–16
Thioridazine S -enantiomer 4–16
Thioridazine R -enantiomer 4–16
Chlorpromazine 1–16
Promazine 16 to >32
aADT, Agar Diffusion Test.
bMac, macrophage.
cBactec, generation of 14CO2 in Bactec 460 System, 12B vials.
*MIC observed against sensitive strains of M. tuberculosis.
**MIC observed against multidrug resistant strains of M. tuberculosis.
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various categories of pharmacological agents since 1976 [17]. 
During their search they were able to detect moderate to 
powerful activity against grampositive and gramnegative 
bacteria in several antihistaminic phenothiazines. One such 
potent compound was methdilazine. In an intensive study, 
Chakrabarty et al. [13] employed 14 different reference 
strains of the genus Mycobacterium and screened them for 
their in vitro action against methdilazine along with two 
known antitubercular agents, streptomycin and rifampicin. 
The regular medium for determining in vitro activity was 
Kirchner’s liquid medium, while the results were subse-
quently confirmed with the help of Lowenstein–Jensen me-
dium. The MIC of methdilazine varied from 5 mg/ml to 12.5 
mg/ml with respect to six test strains of M. tuberculosis; but 
most of the other strains of Mycobacterium were inhibited at 
12.5–15.0 mg/ml of the drug, only except M. gordonae, 
whose MIC was as low as 5.0 mg/ml. Both streptomycin and 
rifampicin were highly effective on these strains, with MIC 
values ranging from 1.0 mg/ml to 2.0 mg/ml in respect of all 
the tested mycobacterial strains. 
In 1996, Amaral and Kristiansen [4] observed that both 
chlorpromazine and thioridazine, another antipsychotic phe-
nothiazine, could inhibit the respiration of clinical isolates 
of multiple drug-resistant M. tuberculosis. All these isolates 
were resistant to isoniazid and at least to another or even 
three of the other antitubercular drugs listed as first-line 
drugs, including streptomycin, rifampicin, ethambutol, and 
pyrazinamide. The authors emphasised that thioridazine, be-
ing much less toxic compared to chlorpromazine, might 
have a greater potential for its usage in freshly diagnosed 
patients of tuberculosis before determining their antibiotic 
sensitivity profile (Table 1). 
Gadre and co-workers [26], while determining the in vi-
tro action of trifluoperazine on clinical isolates of drug sen-
sitive and resistant M. tuberculosis, observed that the MIC 
of trifluo perazine ranged from 4 mg/ml to 8 mg/ml among 
most of the test strains. However, the levels of MIC of tri-
fluoperazine were between 4 mg/ml to16 mg/ml in strains 
that were resistant to one or two common antitubercular 
agents. Gadre et al. [26] further suggested that trifluopera-
zine, being a known calmodulin antagonist, might inhibit 
the growth of tubercle bacilli, which have been shown to 
contain calmodulin-like protein inside their cells (Table 1). 
Ordway and her collaborators [44] became interested in 
determining the intracellular killing capacity of thioridazine 
versus chlorpromazine against sensitive as well as drug-re-
sistant M. tuberculosis with the help of BACTEC 460-TB 
method (Table 1). They observed that both chlorpromazine 
and thioridazine killed intracellular antibiotic sensitive and 
resistant M. tuberculosis at concentrations, in the medium, 
well below those present in the plasma of patients treated 
with these agents for psychosis. Such concentrations in vitro 
were not toxic to macrophages, nor did they have any effect 
on the in vitro cellular immune processes. The authors fur-
ther mentioned that as the phenothiazines are known to be 
concentrated by macrophages that phagocytose and have in 
situ activity against mycobacteria, these agents could be 
considered for use as adjuvants for the management of 
freshly diagnosed tuberculosis in patients from populations 
with a high prevalence of multidrug-resistant tuberculosis. 
Furthermore, chlorpromazine, thioridazine, and prometha-
zine were shown to enhance the activity of rifampicin and 
streptomycin when used in combinations at concentrations 
that are minimally effective when employed separately 
against clinical strains of M. tuberculosis resistant to two or 
more antibiotics (poly-drug-resistant M. tuberculosis). The 
phenothiazines had no effect on the activity of isoniazid 
against test strains of poly-drug-resistant M. tu ber culosis. 
Since the toxic side effects due to systemic administration of 
thioridazine in patients were much lower than those record-
ed after chronic administration of chlorpromazine, Ordway 
et al. [44] postulated that thioridazine could be considered as 
a suitable anti-tubercular drug and could be given to recently 
diagnosed patients suffering from pulmonary tuberculosis.
Van Ingen et al. [54] carried out a detailed in vitro experi-
ment to find out the effect of thioridazine on 25 strains of vari-
ous species of Mycobacterium including 8 strains of M. tuber­
culosis. Susceptibility to thioridazine was tested at concentra-
tions ranging from 1 to 128 µg/ml in Middlebrook 7H10 me-
dium, where sufficient growth of rapid growers was noted after 
4 days and that of slow growers was between 8 and 11 days.
The MIC of thioridazine with respect to all the 8 strains 
of M. tuberculosis (including extremely-drug-resistant, mul-
tidrug-resistant and susceptible mycobacteria) was 4 mg/ml 
(Table 1), whereas the MIC of thioridazine ranged from 16 
mg/ml to 32 mg/ml among most of the other mycobacteria. 
The level of activity of thioridazine against M. abs cessus 
was maximum (64 mg/ml). This particular organism is 
known to cause severe disease in humans, but whether the 
concentration effect of thioridazine is achieved within 
macro phages for infection due to such a bacterium is yet to 
be ascertained [54]. However, with respect to M. kansasii 
type 1 and M. xenopi the MIC of thioridazine was 2 µg/ml 
and 8 µg/ml respectively.
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Properties of selected phenothiazines
A tentative epidemiological cut-off of thioridazine was ob-
tained by Angeby et al. [8] in 51 strains of sensitive M. tuber­
culosis and 67 strains of multidrug-resistant/extremely-drug 
resistant M. tuberculosis with the help of MIC determination 
using Middlebrook 7HI0 medium. Finally, a cut off value of 
16 mg/l was proposed by the authors [8]. Although such a 
concentration was clinically not achievable in serum, thio-
ridazine was found to become concentrated intracellularly 
and an amount of only 0.1 mg/l was able to kill M. tuberculo­
sis cells residing inside cells [8]. The MIC value >16 mg/l 
was found in 6% of multidrug and extremely-drug-resistant 
strains for which the authors stated that resistance mecha-
nism against thioridazine had already been present in the 
drug-resistant clinical strains of M. tuberculosis.
The calmodulin antagonist trifluoperazine was studied in 
detail by Advani et al. [3] for its activity towards M. tubercu­
losis, since such compounds are known to have multiple sites 
of action, including lipid synthesis, DNA processing, protein 
synthesis and respiration. Sensitive wild type, as well as mul-
tidrug-resistant strains of M. tuberculosis, were treated with 
trifluoperazine under different growth conditions of stress, 
including low pH, starvation, presence of nitric oxide and in-
activated THP-1 infectious model. Perturbation in growth ki-
netics of tubercle bacilli at different concentrations of trifluo-
perazine was checked to determine the MIC of trifluoperazine 
per active as also dominant bacterial cells; they observed that 
trifluoperazine was able to significantly reduce the actively 
replicating as well as non-replicating cells of M. tuberculosis, 
thereby producing inhibition in growth of multidrug-resistant 
tuberculosis bacilli (Table 1). Since trifluoperazine showed 
enhanced action against intracellular bacilli, the authors pos-
tulated that this phenothiazine could also get accumulated in 
macrophages. Furthermore, the concentration required to pro-
duce such a phenomenon was non-toxic to macro phages [3].
Organo-silicon compounds are known efflux pump inhibi-
tors and have anti-tubercular activity. One such compound, 
SILA 421, had the same pathway as the other efflux pump 
inhibitors of M. tuberculosis. Furthermore SILA 421 was 
found to modify the mdr-1 efflux pumps of M. tuberculosis 
and could enhance the killing action of M. tuberculosis by 
macrophage. Simons et al. carried out a comparative study to 
find out the efficacy of SILA 421 versus several known anti-
tubercular phenothiazines using 21 clinical isolates of sensi-
tive and resistant M. tuberculosis strains. SILA 421 was found 
to be equally as in vitro as the other well known efflux pump 
inhibitor thioridazine [52] (Table 1).
Methdilazine was assessed in a thoroughly designed in 
vivo experiment using Swiss albino mice. In that test, > 9 × 109 
viable cells of M. tuberculosis H37Rv 102 were given as the 
challenge to two groups of mice, one of which received meth-
dilazine daily. After six weeks, all the animals in both groups 
were sacrificed and bacterial load was determined individu-
ally from liver, spleen, intestine and lung of each animal. The 
results showed that the protective capacity of methdilazine 
was statistically significant. Further studies on the action of 
methdilazine were carried out by Dutta et al. in 2009 [20]. 
They administered methdilazine singly and in combination 
with either streptomycin or isoniazid to separate groups of 
mice infected with M. tuberculosis H37Rv 102. Maintaining 
proper control groups throughout the entire period of investi-
gation, those authors found that, although the combination of 
methdilazine and streptomycin did not result in a significant 
synergism, methdilazine was highly significantly synergistic 
with isoniazid [20].
Apart from methdilazine, the only other phenothiazine 
that has been studied in detail in animal systems is thiorida-
zine. In 2007, Martins and her colleagues [41] tried to evalu-
ate the effectiveness of thioridazine at different dose levels in 
BALB/c mice that had been infected intraperitoneally with a 
high dose of M. tuberculosis ATCC H37Rv, thirty days prior to 
initiation of the treatment. A group of mice receiving no drug 
remained as the control. The dosages of thioridazine, calcu-
lated on the basis of human application, ranged from 0.05 to 
0.5 mg/day. The group of animals that received 0.5 mg of 
thioridazine every day revealed a reduction of the colony 
forming units counts (CFU) in the lungs within 30 days. The 
therapeutic schedule was continued and after 300 days the 
number of mycobacteria in the lungs was found to be dis-
tinctly low. With the help of the same mouse model, van 
Sooligen et al. [55] determined the action of thioridazine in 
separate groups of animals infected with susceptible and mul-
tidrug-resistant M. tuberculosis. After a two-month period of 
oral administration of 32 and 70 mg/kg of thioridazine to two 
separate groups of animals, the CFU in the lungs were re-
duced significantly. Moreover, when thioridazine was added 
to a regimen containing rifampicin, isoniazid and pyrazin-
amide for infection with susceptible bacilli, a statistically sig-
nificant synergistic effect (P < 0.01) was achieved. In a thor-
oughly designed pharmacokinetic study Dutta et al. [54] tried 
to determine the tuberculocidal activity of thioridazine in 
guinea pigs. The animals were aerosol infected with M. tuber­
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culosis and single drug treatment with thioridazine was initi-
ated 4 weeks later. The human equivalent dose of thioridazine 
was determined to be 5 mg/kg, which was given for 5 days per 
week. The initial bacterial burden in the lungs reduced after 
treatment with thioridazine; however, such a reduction was 
less than what was observed in animals treated with isoniazid. 
The tolerance limit of thioridazine in guinea pigs was found to 
be 40 mg/kg [21].
For assessing the activity of thioridazine singly and in 
combination with standard anti-tubercular drugs, single dose 
and steady state pharmacokinetic study [22] were performed 
in BALB/c mice to establish human equivalent doses of thio-
ridazine. In order to determine the bactericidal activity of 
thioridazine against M. tuberculosis, three separate experi-
ments were carried out including a dose ranging study of thio-
ridazine monotherapy and effectiveness of human equivalent 
doses of thioridazine with or without isoniazid/or rifampicin. 
Therapeutic efficacy was assessed by the deviation in myco-
bacterial load in the lungs of test animals. The human-equiva-
lent dose of thioridazine was found to be 25 mg/kg, which 
was very well tolerated by test mice [22]. Furthermore thio-
ridazine was found to accumulate at higher concentrations in 
lung tissue compared to their amount in the serum. The au-
thors also observed that thioridazine was not only synergistic 
with isoniazid, but prevented emergence of isoniazid resistant 
mutants in lung tissues of mice [22].
Multidrug resistance in Mycobacterium 
tuberculosis
Tuberculosis is a highly potent communicable disease world-
wide. The causative organism, M. tuberculosis, is airborne 
and is frequently transmitted from person to person particu-
larly among people of lower income group suffering from 
malnutrition and immunodeficiency. According to the World 
Health Organisation (WHO), in 2012 an estimated 8.6 million 
new cases was reported and 1.3 million died from the disease; 
of those, 320,000 were HIV positive. The distribution pattern 
of cases worldwide showed 29% in South-East Asia, 27% in 
Africa, 19% in Western Pacific regions. Note that India and 
China accounted for 26% and 12% of total cases respectively. 
The treatment regime recommended by the WHO is known as 
Directly Observed Therapy, Short-course (DOTS), in which 
age-old drugs such as isoniazid, rifampicin, ethambutol, and 
pyrazinamide are administered simultaneously for the first 
two months after presumptive diagnosis. Such a schedule is 
followed by a prolonged therapy with isoniazid and rifampi-
cin for subsequent 4–7 months depending on the severity of 
the infection. But this does not guarantee a complete cure 
from the disease state. Moreover, more virulent forms, desig-
nated as multidrug-resistant and extremely drug-resistant tu-
berculosis and their frequent association with HIV has further 
provoked the crisis of the infection.
Mycobacterium tuberculosis resides within the pulmonary 
cavities where the supply of oxygen, pH and nutrition are 
quantitatively very low. The bacterium causes the host to have 
an active immune response during the infection, which results 
in the release of highly reactive oxygen and nitrogen species 
that may at first sight seem toxic to the mycobacterium bacilli. 
But the organism has developed resistance mechanisms to 
counteract that crisis. This resistance accounts for the success 
of M. tuberculosis as an intracellular pathogen. Most antibiot-
ics that are used for the treatment of tuberculosis are only ac-
tive against growing mycobacteria, but not against the dor-
mant pathogens. The correlation between antibiotic activity 
and bacterial growth state in streptomycin-dependent M. tu­
berculosis has been reported. The main reasons for such a re-
sistance are the change in bacterial metabolic pathway or a 
difference in physiological state that is described as pheno-
typic resistance. Due to this phenotypic resistance, the dor-
mant bacilli effectively escape the immune system to the cur-
rent line drugs, although genetic resistance in some organisms 
contributes to the resistance to tuberculosis chemotherapy.
The term multidrug-resistant is applied to those isolates of 
M. tuberculosis that are resistant to isoniazid and rifampicin, 
while extremely-drug-resistant isolates are often resistant to 
isoniazid, rifampicin, streptomycin, any flouroquinolone and 
any of the injectible anti-tuberculosis drugs like amikacin/ka-
namycin/capreomycin. The involvement of multidrug-resis-
tant or extremely-drug-resistant M. tuberculosis strain in an 
infection is often due to misuse or overuse of the scheduled 
drugs or the failure of prolonged therapy that is required to be 
continued for months for the complete cure of the infection. 
Multidrug-resistant/extremely-drug-resistant strains may also 
arise if the treatment schedule is allowed for more than 12 
months as in the case of a new severe infection of tuberculo-
sis. Since many drugs are prescribed and given simultane-
ously for such cases, sufficient pressure is applied to the caus-
ative agent to select multidrug-resistant mutants. Such a situ-
ation could not occur by a single mode of antibacterial action, 
as different drugs have different target sites. A single-point 
mutation for resistance to any type of agents may influence 
the occurrence of resistance to the same class of compounds. 
 
Int. MIcrobIol. Vol. 18, 2015 KRISTIANSEN ET AL.8
However, anti-tubercular drugs are very varied as far as their 
mode of action is concerned. Therefore, structurally similar 
drugs may have the same mutated target. Thus, there is an 
urgent need to use less targeted therapeutics in terms of mi-
crobial anatomy. Multi-site target attack is rather less com-
mon in actual practice. But, usage of such drugs may result in 
damaging the internal microbiota of individuals, particularly 
elderly patients who might easily be infected by opportunistic 
microorganisms [59]. Thus there is a crucial necessity to ex-
plore novel therapeutics with improved activities such as en-
hanced function against multidrug-resistant and extremely-
drug-resistant tuberculosis, rapid mycobactericidal mecha-
nism, and ability to fast penetration of host cells followed by 
bactericidal effect in the intracellular environment.
According to DiMasi et al. [19], the cost of a new drug 
discovery may exceed 800 million USD for a novel chemical 
entity and hence there is insufficient economic incentive for a 
pharmaceutical industry to develop novel drugs against infec-
tious diseases endemic in developing and underdeveloped 
countries. Under such circumstances, the advancement of ex-
isting chemical compounds with well-documented antimicro-
bial potentiality should be explored in order to obtain afford-
able drugs to the great multitude of patients worldwide suffer-
ing from virulent multidrug-resistant infections including tu-
berculosis.
During the past sixty years phenothiazines have turned out 
to be a very important class of compounds owing to their re-
markable biological and pharmacological properties. Several 
studies revealed that they were the first antipsychotics and are 
still the best choice for psychic patients. They are not only 
antibacterial or antifungal, but have many other properties, 
such as antiviral, anticancer, antimalarial, antifilarial, try-
panocidal, antihistaminic, analgesic, anti-inflammatory ac-
tivities. Various studies have further revealed that some phe-
nothiazines are capable of inducing drug resistances in bacte-
ria [43,45]. Phenothiazines are capable of exerting activities 
on biological systems via the interaction of multicyclic ring 
system like π to π interaction or interaction in DNA, or via the 
lipophilic character leading to penetration through biological 
membranes to reach the site of action [45]. The detailed ac-
count of numerous studies presented in this review indicates 
that several phenothiazines act both in vitro and in vivo 
against sensitive as well as multidrug-resistant (MDR) tuber-
cle bacilli. Such active phenothiazines include chlorproma-
zine, methdilazine, trifluoperazine and thioridazine. Many 
researchers have tested chlorpromazine for its potent antibac-
terial and antimalarial properties. This compound, however, 
could not be considered for therapy of bacterial infections due 
to its frequent serious side-effects [5]. But in the early 1980s, 
when multidrug-resistant tuberculosis surfaced in several de-
veloped countries, the search for new anti-tuberculosis com-
pounds became a social necessity. At this time there was a 
resurgence of the anti-tubercular activity of chlorpromazine. 
This activity was ensured at such high concentrations that 
were far beyond those clinically achievable in serum, al-
though it was known that phenothiazines had a great affinity 
for lung tissue which is <100 mg/g wet tissue [28]. Kristiansen 
and Vergmann [35] had reported that all of their test mycobac-
teria were inhibited at <25 mg/ml of chlorpromazine. Hetero-
genous populations of both actively living and latent tubercu-
losis lesions are known to be present in individuals infected 
with tuberculosis.
Several studies [3,13] indicate the action of both trifluo-
perazine and methdilazine that could kill both the above pop-
ulations which implied that the target pathways are common 
to both the multiplying and dormant forms of the organism. 
Multidrug therapy replaced monotherapy in tuberculosis in-
fections since the early 1960s as this was considered to be the 
main cause for the development of drug resistance. Various 
approaches should be used in testing the antimicrobial sus-
ceptibility against M. tuberculosis so that further experiments 
with drug combinations can be made in vivo. The synergistic 
action of phenothiazines with a number of anti-tubercular 
agents has already been reported [20,22]. Both trifluopera-
zine and methdilazine tend to cause accumulation and reten-
tion of antimycobacterial drugs in macrophages. Thus there 
should be approaches for developing more effective and less 
harmful derivatives of such drugs that can be used as an alter-
native to trigger the function of the compound.
Although chlorpromazine was found to kill M. tuberculosis 
in newly phagocytosed human macrophages [4,44] , due to the 
side-effects on the central nervous system, the use of the com-
pound as an anti-tubercular drug remained restricted. Chlor-
promazine was largely replaced by the neuroleptic drug thio-
ridazine, which is less toxic and is much more effective in in 
vitro systems against all forms of antibiotic resistant strains of 
M. tuberculosis and also it has fewer side effects than chlor-
promazine [4]. Thus the interest in thioridazine began; this 
compound promotes the killing of multidrug-resistant M. tuber­
culosis by macrophages, at a much lower concentration used in 
the therapy of psychosis, in the experimental medium [44].
In the murine model, thioridazine has been found to be 
effective against both antibiotic susceptible and multidrug-
resistant tuberculosis infection [41,55]. It has been effective 
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antimicrobial potentialities and reversal of drug resistances 
among pathogenic bacteria [36]. They reported that antimicro-
bial action of phenothiazines and central nervous system ac-
tivity of the same compounds are not related [36]. In their 
studies they further observed that phenothiazines containing 
an exocyclic double bond, termed as thioxanthenes, had a 
more potent antimicrobial activity [36]. However, such thio-
xanthenes acted more intensely on the central nervous system 
than the actual phenothiazines [24,36]. Therefore, there is a 
possibility to separate central nervous system and antimicro-
bial functions by synthesising isomeric forms of the same-
compound with an additional halogen moiety, which is known 
to potentiate antimicrobial action [36].
Classical phenothiazine compounds having different ste-
reoisomeric forms (+/–) have distinct differences in produc-
ing antimicrobial action [32,36,53]. In 2013, Christensen et al. 
[15] made a detailed comparative analysis on the in vitro and 
in vivo efficacies of the (+) and (–) enantiomers of thiorida-
zine along with its racemic form. Their study yielded a sig-
nificant antibacterial action in all the forms of thioridazine, 
indicating of further the levorotatory (–) form to be superior 
in terms of both its in vitro and in vivo efficacies [15]. Since 
the racemic form of thioridazine containing both (+) and (–) is 
known to possess very potent anti-mycobacterial action [36] 
the (–) thioridazine with no central nervous system activity 
should lead to a breakthrough in the treatment of tuberculosis, 
particularly synergistic action of thioridazine with isoniazid 
[22] should also be further investigated with this form in vitro 
and in vivo. Thus all the recent studies presented here have 
established the addition of thioridazine to the existing com-
bined regimen for the treatment of multidrug-resistant and 
extremely-drug-resistant M. tuberculosis. 
One hundred years ago Paul Ehrlich had been treating pa-
tients suffering from trypanosomiasis and malaria with the 
help of methylene blue, the first ever compound of phenothi-
azines. Since the late 1940s the entire class of phenothiazines 
has evolved not only as neuroleptics but also as antimicrobi-
als. The potentiality of thioridazine as a highly suitable candi-
date for multidrug-resistant/extremely-drug-resistant tubercu-
losis has been repeatedly proved in Argentina, where patients 
dying from infection by extremely drug-resistant tuberculosis 
were cured with a combination of linezolid, moxifloxacin and 
thioridazine [1]. In this way this review offers a new horizon 
for successful therapy of patients suffering from multidrug-
resistant/extremely-drug-resistant tuberculosis with thiorida-
zine, preferably its levorotatory form, as a drug additional to 
the list of conventional therapeutic regimen.
also against ten out of twelve cases of extremely-drug-resis-
tant tuberculosis patients [6]. Therefore, the therapy of ex-
tremely-drug-resistant tuberculosis may be conducted on a 
compassionate basis with thioridazine plus standard therapeu-
tic regimen.
Chlorpromazine has been found to affect the bacterial ef-
flux pump; therefore, it reduces the resistance to antibiotics in 
bacterial strains [56]. The result was found to be similar in the 
case of phenothiazines. They could inhibit Nor A efflux pump 
of Staphylococcus aureus and the QAC efflux pump of plas-
mid-carrying multidrug-resistant Staphylococcus aureus [33]. 
The Acr AB efflux pump of E.coli was found to be inhibited 
by both phenothiazines, chlorpromazine and thioridazine 
[57]. These phenothiazines could also inhibit the main efflux 
pump of M. smegmatis and the efflux pump of M. avium [48].
Since it affects the survival genes of M. tuberculosis, the ef-
fect of thioridazine may presumably be universal. Phenothi-
azines act by inhibiting the activity of calcium-dependent 
ATPase, which leads to the acidification of phagolysosome 
and its subsequent activation of the hydrolases, resulting in 
the inhibition of replication of the bacterium [7]. Thioridazine 
inhibits the EmrE-encoded efflux pump in M. tuberculosis 
[49]. Further, thioridazine treated cell cause the expression of 
Rv3065 gene, which encodes the multidrug transport integral 
membrane protein EmrE, and that of another putative efflux 
pump gene Rv1634. When Rv3065 homologue is deleted in 
M. smegmatis, it has been seen that there is an increased sus-
ceptibility to a number of drugs including fluoroquinolones, 
ethidium bromide, and acriflavin [49].
During the macrophage infection by M. tuberculosis, the 
action of several efflux pumps and their regulators induce the 
tolerance of thioridazine inside the mycobacterial cell [2]. The 
accumulation of mutations in isoniazid targets is caused by the 
overexpression of the efflux pumps and the treatment with thio-
ridazine, chlorpromazine and verapamil can reduce the resis-
tance of M. tuberculosis to isoniazid [38]. Efflux pump inhibi-
tors enhance the killing of intracellular M. tuberculosis by non-
killing macrophages. Thioridazine is able to inhibit the expres-
sion of efflux pumps in M. tuberculosis in such a manner that 
the anti-mycobacterial drugs fail to arrive at their intended tar-
gets in the cell. Thioridazine can also inhibit the activity of ex-
isting efflux pumps that are responsible for the multidrug-resis-
tant phenotype of M. tuberculosis. Thus, for preventing the 
emergence of multidrug-resistance tuberculosis thioridazine 
should be used for developing new therapeutic strategies [38]. 
Kristiansen and her co-workers probed on various proper-
ties of phenothiazines including inhibiting potassium efflux, 
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Conclusion
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have led to an alarming situation in all the continents. Al-
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losis in BALB/c mice is rather small due to its unique prop-
erty of being concentrated inside macrophages that host tu-
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screening of antitubercular drug claimed that the human 
equivalent dose of thioridazine was well tolerated by test ani-
mals and that thioridazine was found to accumulate at high 
concentrations in lung tissues compared to serum levels. 
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for the treatment of the multidrug-resistant/extremely-drug- 
resistant tuberculosis a new avenue will open up by synthesis-
ing and initiating clinical trials with (–) thioridazine to facili-
tate an orchestrated response against this deadly pathogen.
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